Life Sciences and Healthcare

R&D spend up, capital down makes for shorter runways for midmarket biotech companies

Spending on R&D by midmarket biotech companies increased 18 percent from 2015 to 2016, from an average of $65.9 million to an average of $80.6 million, according to the 2017 BDO Biotech Briefing, a report from BDO USA LLP analyzing the 10-K SEC filings from companies in the Nasdaq Biotechnology Index (NBI) with revenue of less than $300 million.

Lung cancer – continued progress in personalized care

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry.

DCAT Sharp Sourcing session focuses on best practices

DCAT Sharp Sourcing, a one-day conference organized by the Drug, Chemical & Associated Technologies Association (DCAT), brought together executives representing the entire pharmaceutical value chain, ranging from raw materials to finished drug product manufacturing and packaging.

Checkpoint inhibitors: a cutting edge in oncology

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry.

Promoting Customer Satisfaction in Healthcare

Although providing excellent customer service is a necessary component for the success of most businesses, the healthcare industry has typically been slower to adapt practices that place a heavy focus on customer satisfaction. In fact, according to the American Customer Satisfaction Index‘s 2017 Utilities, Shipping, and Health Care Report, hospitals achieved a customer satisfaction score of 75 […]